Emergent Biosolutions
EBS
299 hedge funds and large institutions have $3.56B invested in Emergent Biosolutions in 2020 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 97 increasing their positions, 110 reducing their positions, and 24 closing their positions.
167% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 24
53% more call options, than puts
Call options by funds: $7.43M | Put options by funds: $4.85M
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
37% more capital invested
Capital invested by funds: $2.61B → $3.56B (+$955M)
15% more funds holding
Funds holding: 261 → 299 (+38)
1.14% less ownership
Funds ownership: 86.98% → 85.84% (-1.1%)
12% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 110
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$47.4M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$26.6M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$23M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$21.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
-$92.4M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$22.2M |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$19.6M |
| 4 |
Renaissance Technologies
New York
|
-$17.8M |
| 5 |
Goldman Sachs
New York
|
-$15.1M |
EBS Hedge Fund Activity: Q2 2020 in Review
299 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2020, worth a combined $3.56B — up 37% from $2.61B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new EBS positions and 24 closed out — a net gain of 40 holders — while 97 added to existing stakes and 110 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $47.4M. The largest seller was EARNEST Partners, cutting an estimated $92.4M.
- 299 institutional investors held Emergent Biosolutions (EBS) as of Q2 2020, up from 261 in Q1 2020.
- Funds reported $3.56B of Emergent Biosolutions stock for Q2 2020, up 37% quarter-over-quarter.
- 64 funds opened new Emergent Biosolutions positions in Q2 2020 and 24 closed out, a net change of +40 holders.
- The largest Emergent Biosolutions buyer in Q2 2020 was Neuberger Berman Group, an estimated $47.4M added.
- The largest Emergent Biosolutions seller in Q2 2020 was EARNEST Partners, an estimated $92.4M sold.
Based on aggregated 13F filings for Q2 2020.